Charcot-Marie-Tooth Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major Charcot-Marie-Tooth disease markets reached a value of US$ 814.5 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 8,995.2 Million by 2034, exhibiting a growth rate (CAGR) of 24.4% during 2024-2034.
The Charcot-Marie-Tooth disease market has been comprehensively analyzed in IMARC's new report titled "Charcot-Marie-Tooth Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Charcot-Marie-Tooth (CMT) disease is a rare genetic disorder that affects the peripheral nerves responsible for muscle movement and sensation. It is characterized by muscle weakness, atrophy, and sensory loss in the feet, legs, hands, and forearms. These symptoms often start in childhood or adolescence and progress slowly over time. Some other indications may include foot deformities, such as high arches or flat feet, difficulty with balance and coordination, etc. The diagnosis of Charcot-Marie-Tooth disease typically involves a combination of clinical evaluation, family history assessment, and genetic testing. A neurological exam is utilized to reveal muscle weakness and atrophy, decreased reflexes, and sensory loss in the hands and feet. Additionally, blood tests aid in identifying genetic mutations associated with the disease and electromyography (EMG) measures the speed and strength of nerve impulses in the affected limbs. Besides this, magnetic resonance imaging (MRI) and nerve biopsies are also used to confirm the diagnosis and rule out other conditions with similar symptoms.
The rising prevalence of genetic disorders and the increasing unmet medical need for novel therapies that can halt or slow the progression of the ailment are primarily driving the Charcot-Marie-Tooth disease market. Besides this, the escalating utilization of antioxidants, such as alpha-lipoic acid and vitamin E, for improving nerve function in patients with CMT disease is further bolstering the market growth. Moreover, the widespread adoption of nerve conduction studies for diagnosing the disorder since they can detect abnormalities in nerve conduction and aid in distinguishing between different types of CMT disease is also creating a positive outlook for the market. Additionally, several government bodies are providing support for rare disease research and drug development through grants and tax incentives to understand the ailment better and launch effective treatments. This, in turn, is acting as another significant growth-inducing factor. Furthermore, the emerging popularity of small molecule drugs, such as ascorbic acid and ganglioside GM1, which aid in promoting nerve regeneration and enhancing motor function in patients, is also augmenting the market growth. Apart from this, the introduction of custom-made orthotics and braces, which assist in improving the quality of life for CMT patients by reducing symptoms and increasing mobility, is expected to drive the Charcot-Marie-Tooth disease market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the Charcot-Marie-Tooth disease market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for Charcot-Marie-Tooth disease and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Charcot-Marie-Tooth disease market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the Charcot-Marie-Tooth disease market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the Charcot-Marie-Tooth disease market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current Charcot-Marie-Tooth disease marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the Charcot-Marie-Tooth disease market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the Charcot-Marie-Tooth disease market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the Charcot-Marie-Tooth disease market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of Charcot-Marie-Tooth disease across the seven major markets?
What is the number of prevalent cases (2018-2034) of Charcot-Marie-Tooth disease by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of Charcot-Marie-Tooth disease by gender across the seven major markets?
What is the number of prevalent cases (2018-2034) of Charcot-Marie-Tooth disease by type across the seven major markets?
How many patients are diagnosed (2018-2034) with Charcot-Marie-Tooth disease across the seven major markets?
What is the size of the Charcot-Marie-Tooth disease patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of Charcot-Marie-Tooth disease?
What will be the growth rate of patients across the seven major markets?
Charcot-Marie-Tooth Disease: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for Charcot-Marie-Tooth disease drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Charcot-Marie-Tooth disease market?
What are the key regulatory events related to the Charcot-Marie-Tooth disease market?
What is the structure of clinical trial landscape by status related to the Charcot-Marie-Tooth disease market?
What is the structure of clinical trial landscape by phase related to the Charcot-Marie-Tooth disease market?
What is the structure of clinical trial landscape by route of administration related to the Charcot-Marie-Tooth disease market?
The Charcot-Marie-Tooth disease market has been comprehensively analyzed in IMARC's new report titled "Charcot-Marie-Tooth Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Charcot-Marie-Tooth (CMT) disease is a rare genetic disorder that affects the peripheral nerves responsible for muscle movement and sensation. It is characterized by muscle weakness, atrophy, and sensory loss in the feet, legs, hands, and forearms. These symptoms often start in childhood or adolescence and progress slowly over time. Some other indications may include foot deformities, such as high arches or flat feet, difficulty with balance and coordination, etc. The diagnosis of Charcot-Marie-Tooth disease typically involves a combination of clinical evaluation, family history assessment, and genetic testing. A neurological exam is utilized to reveal muscle weakness and atrophy, decreased reflexes, and sensory loss in the hands and feet. Additionally, blood tests aid in identifying genetic mutations associated with the disease and electromyography (EMG) measures the speed and strength of nerve impulses in the affected limbs. Besides this, magnetic resonance imaging (MRI) and nerve biopsies are also used to confirm the diagnosis and rule out other conditions with similar symptoms.
The rising prevalence of genetic disorders and the increasing unmet medical need for novel therapies that can halt or slow the progression of the ailment are primarily driving the Charcot-Marie-Tooth disease market. Besides this, the escalating utilization of antioxidants, such as alpha-lipoic acid and vitamin E, for improving nerve function in patients with CMT disease is further bolstering the market growth. Moreover, the widespread adoption of nerve conduction studies for diagnosing the disorder since they can detect abnormalities in nerve conduction and aid in distinguishing between different types of CMT disease is also creating a positive outlook for the market. Additionally, several government bodies are providing support for rare disease research and drug development through grants and tax incentives to understand the ailment better and launch effective treatments. This, in turn, is acting as another significant growth-inducing factor. Furthermore, the emerging popularity of small molecule drugs, such as ascorbic acid and ganglioside GM1, which aid in promoting nerve regeneration and enhancing motor function in patients, is also augmenting the market growth. Apart from this, the introduction of custom-made orthotics and braces, which assist in improving the quality of life for CMT patients by reducing symptoms and increasing mobility, is expected to drive the Charcot-Marie-Tooth disease market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the Charcot-Marie-Tooth disease market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for Charcot-Marie-Tooth disease and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Charcot-Marie-Tooth disease market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the Charcot-Marie-Tooth disease market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the Charcot-Marie-Tooth disease market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current Charcot-Marie-Tooth disease marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the Charcot-Marie-Tooth disease market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the Charcot-Marie-Tooth disease market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the Charcot-Marie-Tooth disease market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of Charcot-Marie-Tooth disease across the seven major markets?
What is the number of prevalent cases (2018-2034) of Charcot-Marie-Tooth disease by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of Charcot-Marie-Tooth disease by gender across the seven major markets?
What is the number of prevalent cases (2018-2034) of Charcot-Marie-Tooth disease by type across the seven major markets?
How many patients are diagnosed (2018-2034) with Charcot-Marie-Tooth disease across the seven major markets?
What is the size of the Charcot-Marie-Tooth disease patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of Charcot-Marie-Tooth disease?
What will be the growth rate of patients across the seven major markets?
Charcot-Marie-Tooth Disease: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for Charcot-Marie-Tooth disease drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Charcot-Marie-Tooth disease market?
What are the key regulatory events related to the Charcot-Marie-Tooth disease market?
What is the structure of clinical trial landscape by status related to the Charcot-Marie-Tooth disease market?
What is the structure of clinical trial landscape by phase related to the Charcot-Marie-Tooth disease market?
What is the structure of clinical trial landscape by route of administration related to the Charcot-Marie-Tooth disease market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 CHARCOT-MARIE-TOOTH DISEASE - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-20343)
4.5 Competitive Intelligence
5 CHARCOT-MARIE-TOOTH DISEASE - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 CHARCOT-MARIE-TOOTH DISEASE - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Epidemiology by Type (?2018-2034?)
7.2.6 Diagnosed Cases (?2018-2034?)
7.2.7 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Epidemiology by Type (?2018-2034?)
7.3.6 Diagnosed Cases (?2018-2034?)
7.3.7 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Epidemiology by Type (?2018-2034?)
7.4.6 Diagnosed Cases (?2018-2034?)
7.4.7 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Epidemiology by Type (?2018-2034?)
7.5.6 Diagnosed Cases (?2018-2034?)
7.5.7 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Epidemiology by Type (?2018-2034?)
7.6.6 Diagnosed Cases (?2018-2034?)
7.6.7 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Epidemiology by Type (?2018-2034?)
7.7.6 Diagnosed Cases (?2018-2034?)
7.7.7 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Epidemiology by Type (?2018-2034?)
7.8.6 Diagnosed Cases (?2018-2034?)
7.8.7 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Epidemiology by Type (?2018-2034?)
7.9.6 Diagnosed Cases (?2018-2034?)
7.9.7 Patient Pool/Treated Cases (?2018-2034?)
8 CHARCOT-MARIE-TOOTH DISEASE - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 CHARCOT-MARIE-TOOTH DISEASE - UNMET NEEDS
10 CHARCOT-MARIE-TOOTH DISEASE - KEY ENDPOINTS OF TREATMENT
11 CHARCOT-MARIE-TOOTH DISEASE - MARKETED PRODUCTS
11.1 List of Charcot-Marie-Tooth Disease Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 CHARCOT-MARIE-TOOTH DISEASE - PIPELINE DRUGS
12.1 List of Charcot-Marie-Tooth Disease Pipeline Drugs Across the Top 7 Markets
12.1.1 EN001 - ENCell
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 PXT3003 - Pharnext
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 VM202 - Helixmith
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. CHARCOT-MARIE-TOOTH DISEASE - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. CHARCOT-MARIE-TOOTH DISEASE – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 CHARCOT-MARIE-TOOTH DISEASE - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Charcot-Marie-Tooth Disease - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Charcot-Marie-Tooth Disease - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Charcot-Marie-Tooth Disease - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Charcot-Marie-Tooth Disease - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Charcot-Marie-Tooth Disease - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Charcot-Marie-Tooth Disease - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Charcot-Marie-Tooth Disease - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Charcot-Marie-Tooth Disease - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Charcot-Marie-Tooth Disease - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Charcot-Marie-Tooth Disease - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Charcot-Marie-Tooth Disease - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Charcot-Marie-Tooth Disease - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Charcot-Marie-Tooth Disease - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Charcot-Marie-Tooth Disease - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Charcot-Marie-Tooth Disease - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Charcot-Marie-Tooth Disease - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Charcot-Marie-Tooth Disease - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Charcot-Marie-Tooth Disease - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Charcot-Marie-Tooth Disease - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Charcot-Marie-Tooth Disease - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Charcot-Marie-Tooth Disease - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Charcot-Marie-Tooth Disease - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Charcot-Marie-Tooth Disease - Access and Reimbursement Overview
16 CHARCOT-MARIE-TOOTH DISEASE - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 CHARCOT-MARIE-TOOTH DISEASE MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 CHARCOT-MARIE-TOOTH DISEASE MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 CHARCOT-MARIE-TOOTH DISEASE - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-20343)
4.5 Competitive Intelligence
5 CHARCOT-MARIE-TOOTH DISEASE - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 CHARCOT-MARIE-TOOTH DISEASE - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Epidemiology by Type (?2018-2034?)
7.2.6 Diagnosed Cases (?2018-2034?)
7.2.7 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Epidemiology by Type (?2018-2034?)
7.3.6 Diagnosed Cases (?2018-2034?)
7.3.7 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Epidemiology by Type (?2018-2034?)
7.4.6 Diagnosed Cases (?2018-2034?)
7.4.7 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Epidemiology by Type (?2018-2034?)
7.5.6 Diagnosed Cases (?2018-2034?)
7.5.7 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Epidemiology by Type (?2018-2034?)
7.6.6 Diagnosed Cases (?2018-2034?)
7.6.7 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Epidemiology by Type (?2018-2034?)
7.7.6 Diagnosed Cases (?2018-2034?)
7.7.7 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Epidemiology by Type (?2018-2034?)
7.8.6 Diagnosed Cases (?2018-2034?)
7.8.7 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Epidemiology by Type (?2018-2034?)
7.9.6 Diagnosed Cases (?2018-2034?)
7.9.7 Patient Pool/Treated Cases (?2018-2034?)
8 CHARCOT-MARIE-TOOTH DISEASE - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 CHARCOT-MARIE-TOOTH DISEASE - UNMET NEEDS
10 CHARCOT-MARIE-TOOTH DISEASE - KEY ENDPOINTS OF TREATMENT
11 CHARCOT-MARIE-TOOTH DISEASE - MARKETED PRODUCTS
11.1 List of Charcot-Marie-Tooth Disease Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 CHARCOT-MARIE-TOOTH DISEASE - PIPELINE DRUGS
12.1 List of Charcot-Marie-Tooth Disease Pipeline Drugs Across the Top 7 Markets
12.1.1 EN001 - ENCell
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 PXT3003 - Pharnext
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 VM202 - Helixmith
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. CHARCOT-MARIE-TOOTH DISEASE - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. CHARCOT-MARIE-TOOTH DISEASE – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 CHARCOT-MARIE-TOOTH DISEASE - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Charcot-Marie-Tooth Disease - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Charcot-Marie-Tooth Disease - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Charcot-Marie-Tooth Disease - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Charcot-Marie-Tooth Disease - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Charcot-Marie-Tooth Disease - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Charcot-Marie-Tooth Disease - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Charcot-Marie-Tooth Disease - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Charcot-Marie-Tooth Disease - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Charcot-Marie-Tooth Disease - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Charcot-Marie-Tooth Disease - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Charcot-Marie-Tooth Disease - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Charcot-Marie-Tooth Disease - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Charcot-Marie-Tooth Disease - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Charcot-Marie-Tooth Disease - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Charcot-Marie-Tooth Disease - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Charcot-Marie-Tooth Disease - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Charcot-Marie-Tooth Disease - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Charcot-Marie-Tooth Disease - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Charcot-Marie-Tooth Disease - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Charcot-Marie-Tooth Disease - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Charcot-Marie-Tooth Disease - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Charcot-Marie-Tooth Disease - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Charcot-Marie-Tooth Disease - Access and Reimbursement Overview
16 CHARCOT-MARIE-TOOTH DISEASE - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 CHARCOT-MARIE-TOOTH DISEASE MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 CHARCOT-MARIE-TOOTH DISEASE MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
